Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs SPDR Kensho Final Frontiers ETF (ROKT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs SPDR Kensho Final Frontiers ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.19 (market cap $12.58B), while SPDR Kensho Final Frontiers ETF trades at $102.69 (market cap $170.14M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 73.9× SPDR Kensho Final Frontiers ETF's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and SPDR Kensho Final Frontiers ETF for 8 Days on average.
| HALO | ROKT | |
|---|---|---|
Market Cap | $12.58B | $170.14M |
Volume | 2,179,278 | 12,298 |
Sector | Health | Sector/Thematic |
52-Week High | $115.22 | $136.68 |
52-Week Low | $61.63 | $72.93 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $14.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About SPDR Kensho Final Frontiers ETF
SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →
